AdaptHealth (NASDAQ:AHCO) initiated with Buy rating and $17 (31% upside) price target at Stifel.
DURECT (NASDAQ:DRRX) initiated with Buy rating and $5 (158% upside) price target at B. Riley FBR. Shares up 6% premarket.
InMed Pharmaceuticals (IN CN) initiated with Buy rating and C$1.50 (341% upside) price target at Maxim Group (OTCQX:IMLFF).
Neptune Wellness Solutions (NEPT CN) initiated with Market Perform rating and C$3.75 (14% upside) (NASDAQ:NEPT).
Phreesia (NYSE:PHR) initiated with Overweight rating and $36 (15% upside) price target at KeyBanc.
Arena Pharmaceuticals (NASDAQ:ARNA) upgraded to Overweight with a $58 (32% upside) price target at JPMorgan. Shares up 2% premarket.
United Therapeutics (NASDAQ:UTHR) upgraded to Overweight with a $120 (25% upside) price target at JPMorgan.
Amgen (NASDAQ:AMGN) downgraded to Underperform with a $185 (18% downside risk) price target at Baird on soft 2020 guidance. Shares down 3% premarket.
Global Blood Therapeutics (NASDAQ:GBT) downgraded to Hold with a $75 (10% upside) price target at SunTrust Robinson Humphrey.
Intra-Cellular Therapies (NASDAQ:ITCI) downgraded to Neutral with a $26 (13% upside) price target at JPMorgan. Shares down 9% premarket.
ResMed (NYSE:RMD) downgraded to Neutral at UBS after FQ2 results.
Rubius Therapeutics (NASDAQ:RUBY) downgraded to Neutral with a $9 (17% upside) price target at JPMorgan. Shares down 5% premarket.
https://seekingalpha.com/news/3536846-baird-downgrades-amgen-on-soft-guidance-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.